Goserelin
Last Updated: 06/30/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 2171 publications
Fovinaciclib for First-Line Therapy of Advanced Breast Cancer: A Randomized Clinical Trial.
Journal: JAMA oncology
Published: June 01, 2026
Diagnostic challenges and management of primary accessory axillary breast cancer.
Journal: BMJ case reports
Published: April 24, 2026
Interstitial lung disease associated with antiandrogen agents: a pharmacovigilance study based on FDA adverse event reporting system.
Journal: International urology and nephrology
Published: March 17, 2026
Pathological complete response to perioperative treatment with darolutamide plus ADT in locally advanced prostate cancer without PTEN or RB1 loss: a case report.
Journal: Frontiers in pharmacology
Published: March 13, 2026
Meta-analysis of the effect of goserelin acetate implant on improving hormone levels in patients with endometriosis.
Journal: Pakistan journal of pharmaceutical sciences
Published: February 28, 2026
Thoracoabdominal endometriosis mimicking pulmonary tuberculosis in a TB-endemic setting: a case report.
Journal: Journal of medical case reports
Published: February 14, 2026
Challenges in analyzing real-world evidence: analysis of androgen deprivation therapy use for prostate cancer in the REASSURE study.
Journal: ESMO real world data and digital oncology
Published: February 06, 2026
Bilateral invasive lobular breast carcinoma with synchronous gastric metastasis and orbital pseudotumor mimicking metastasis: a case report.
Journal: Discover oncology
Published: January 23, 2026
Roles of Goserelin in Gynecological Disorders.
Journal: Drug design, development and therapy
Published: January 14, 2026
Sex and age disparities in goserelin safety: a global pharmacovigilance study.
Journal: Naunyn-Schmiedeberg's archives of pharmacology
Published: January 12, 2026
Arabic translation, cross-cultural adaptation, feasibility, acceptability, and initial psychometric evaluation of the hot flushes diary and the hot flush rating scale and diary interference scale (HFRDIS) in young breast cancer survivors.
Journal: Journal of patient-reported outcomes
Published: January 09, 2026
Last Updated: 06/30/2026